Dose-ranging effects of SGLT2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis
Lana Catani Ferreira Pinto, Dimitris Rucks Varvaki Rados, Luciana Reck Remonti, Marina Verçoza Viana, Cristiane Bauermann Leitão, Jorge Luiz Gross
Abstract
and body weight. The remaining medications and dosages were clinically similar, despite some statistically significant differences among them. Canagliflozin 300 mg seems to be more potent in reducing HbA1c and body weight in patients with type 2 diabetes. The remaining SGLT2 inhibitors at different doses lead to similar effects for both outcomes. Whether these glycemic and weight effects are reflected in lower mortality and cardiovascular events is still uncertain and may be a topic for further studies.
Topics & Concepts
MedicineCanagliflozinEmpagliflozinDapagliflozinMeta-analysisGlycated hemoglobinType 2 diabetesGlycemicDiabetes mellitusInternal medicineRandomized controlled trialDoseWeight lossEndocrinologyObesityDiabetes Treatment and ManagementPancreatic function and diabetesDiabetes Management and Research